First-in-Human Study of TAK-280 in Participants With Solid Tumors
1/2期
提前终止
NCT05220098
| 适应症 | Unresectable Locally Advanced or Metastatic Cancer |
|---|
| 分期 | 1/2期 |
|---|
| 申办方 | Takeda |
|---|
| 状态 | 提前终止 |
|---|
| 受试者人数 | 69 人 |
|---|
| 干预（药物） | TAK-280 |
|---|
| 开始日期 | 2022年4月21日 |
|---|
| 完成日期 | 2025年7月28日 |
|---|
| 结果公布日 | 2026年7月7日 |
|---|
摘要
The main aim of this study is to find out the safety, tolerability, and effect of TAK- 280 in participants with unresectable, locally advanced or metastatic cancer who have experienced treatment failure or are intolerant to standard therapies. Participants will be treated with TAK-280 for up to 14 treatment cycles. Each treatment cycle will be 28 days. After the last dose of study drug, participants will be followed up for survival every 12 weeks for a total of 48 weeks.
Number of Participants With Dose Limiting Toxicities (DLTs)
Cycle 1 (Cycle length=28 days) · Participants
| TAK-280, Dose A | 0 Participants |
|---|
| TAK-280, Dose B | 0 Participants |
|---|
| TAK-280, Dose C | 0 Participants |
|---|
| TAK-280, Dose D | 2 Participants |
|---|
| TAK-280, Dose E | 0 Participants |
|---|
| TAK-280, Dose F | 1 Participants |
|---|
Number of Participants With One or More Treatment-emergent Adverse Events (TEAEs)
From start of study drug administration up to follow-up (up to 37 weeks) · Participants
| TAK-280, Dose A | 2 Participants |
|---|
| TAK-280, Dose B | 1 Participants |
|---|
| TAK-280, Dose C | 3 Participants |
|---|
| TAK-280, Dose D | 5 Participants |
|---|
| TAK-280, Dose E | 5 Participants |
|---|
| TAK-280, Dose F | 5 Participants |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。